Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AKCEA THERAPEUTICS, INC.AKCA · Entity 145982 | Director | July 13, 2017 | July 13, 2017 |
| IONIS PHARMACEUTICALS INCIONS · Entity 1182 | Director · Exec Chairman of the Board | January 26, 2021 | January 29, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AKCEA THERAPEUTICS, INC.
Report date July 13, 2017 · Filed July 13, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| No securities are beneficially owned.SEC Table I · non-derivative | Direct | 0 |
Reported balance
Holding disclosure · report date 2017-07-13 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 0 |
IONIS PHARMACEUTICALS INC
Report date January 26, 2021 · Filed January 29, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,021 |
Reported balance
After 2021-01-26 transaction · row 1
1 source rowRow 1 · 2021-01-26 · Sale · Disposed 28,333 · Balance 2,021 F1: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on January 2, 2020. F2: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.00 to $64.00, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) of this Form 4. |
| Common StockSEC Table I · non-derivative | IndirectBy wife | 3,111 |
Reported balance
Holding disclosure · report date 2021-01-26 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 3,111 |
| Common StockSEC Table I · non-derivative | IndirectBy trust | 494,391 |
Reported balance
Holding disclosure · report date 2021-01-26 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 494,391 |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on January 2, 2020.
F2: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.00 to $64.00, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) of this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 26, 2021 Filed Jan 29, 2021 00:22 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 28,333 | $63.74 | $1,805,812.25 |
DisclosureSEC source: 0000874015-21-000051 · edgar.xml · nonDerivative · entry 1 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,021 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on January 2, 2020. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.00 to $64.00, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) of this Form 4. Read SEC document |
| January 22, 2021 Filed Jan 26, 2021 01:24 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 40,000 | $61.68 | $2,467,000.00 |
DisclosureSEC source: 0000874015-21-000047 · edgar.xml · nonDerivative · entry 3 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Indirect · By trust Disclosed balance after: 494,391 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on January 2, 2020. F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.00 to $62.00, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) of this Form 4. Read SEC document |
| January 21, 2021 Filed Jan 26, 2021 01:24 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 21,042 | $61.65 | $1,297,239.30 |
DisclosureSEC source: 0000874015-21-000047 · edgar.xml · nonDerivative · entry 2 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Indirect · By trust Disclosed balance after: 534,391 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on January 2, 2020. F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.25 to $62.15, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) of this Form 4. Read SEC document |
| January 21, 2021 Filed Jan 26, 2021 01:24 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 13,958 | $60.53 | $844,877.74 |
DisclosureSEC source: 0000874015-21-000047 · edgar.xml · nonDerivative · entry 1 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Indirect · By trust Disclosed balance after: 555,433 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on January 2, 2020. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.20 to $61.00, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) of this Form 4. Read SEC document |
| January 15, 2021 Filed Jan 21, 2021 00:12 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Units · Derivative | 4,371 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-21-000045 · edgar.xml · derivative · entry 8 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 7,801 Underlying: Common Stock · 4,371 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. Read SEC document |
| January 15, 2021 Filed Jan 21, 2021 00:12 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Units · Derivative | 47,257 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-21-000045 · edgar.xml · derivative · entry 7 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,885 Underlying: Common Stock · 47,257 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. Read SEC document |
| January 15, 2021 Filed Jan 21, 2021 00:12 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantRestricted Stock Units · Derivative | 5,333 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-21-000045 · edgar.xml · derivative · entry 6 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,333 Underlying: Common Stock · 5,333 shares Expires not disclosed F3 · derivative.exercise_price: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. Read SEC document |
| January 15, 2021 Filed Jan 21, 2021 00:12 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Tax withholdingCommon Stock | 1,434 | $61.28 | $87,875.52 |
DisclosureSEC source: 0000874015-21-000045 · edgar.xml · nonDerivative · entry 4 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 3,111 F2 · kind: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. F2 · shares: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Read SEC document |
| January 15, 2021 Filed Jan 21, 2021 00:12 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 4,371 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-21-000045 · edgar.xml · nonDerivative · entry 3 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 4,545 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards. F1 · shares: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards. Read SEC document |
| January 15, 2021 Filed Jan 21, 2021 00:12 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Tax withholdingCommon Stock | 18,924 | $61.28 | $1,159,662.72 |
DisclosureSEC source: 0000874015-21-000045 · edgar.xml · nonDerivative · entry 2 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,354 F2 · kind: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. F2 · shares: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Read SEC document |
| January 15, 2021 Filed Jan 21, 2021 00:12 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 47,257 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-21-000045 · edgar.xml · nonDerivative · entry 1 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,278 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards. F1 · shares: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards. Read SEC document |
| January 04, 2021 Filed Jan 7, 2021 02:20 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantEmployee Stock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $56.78 | $0.00 |
DisclosureSEC source: 0000874015-21-000017 · edgar.xml · derivative · entry 1 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2028-01-03 F1 · derivative.exercise_date: Grant on 01/04/2021 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/04/2021. 25% of the shares subject to the option will vest and become exercisable on 01/04/2022. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years. Read SEC document |
| December 17, 2020 Filed Dec 18, 2020 00:42 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 1,407 | $50.50 | $71,053.50 |
DisclosureSEC source: 0000874015-20-000172 · edgar.xml · nonDerivative · entry 2 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Indirect · by wife Disclosed balance after: 174 F3 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person's wife on January 2, 2020. Read SEC document |
| December 15, 2020 Filed Dec 18, 2020 00:42 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 39,000 | $49.78 | $1,941,225.00 |
DisclosureSEC source: 0000874015-20-000172 · edgar.xml · nonDerivative · entry 1 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Indirect · by trust Disclosed balance after: 600,391 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on January 2, 2020. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.50 to $50.00, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) of this Form 4. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 01:14 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 6,000 | $51.50 | $309,000.00 |
DisclosureSEC source: 0000874015-20-000170 · edgar.xml · nonDerivative · entry 2 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Indirect · by trust Disclosed balance after: 639,391 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on January 2, 2020. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 01:14 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 5,000 | $51.87 | $259,350.50 |
DisclosureSEC source: 0000874015-20-000170 · edgar.xml · nonDerivative · entry 1 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Indirect · by trust Disclosed balance after: 645,391 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on January 2, 2020. Read SEC document |
| November 25, 2020 Filed Nov 30, 2020 23:48 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 12,990 | $0.00 Strike: $39.87 | $0.00 |
DisclosureSEC source: 0000874015-20-000158 · edgar.xml · derivative · entry 5 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 0 shares Expires 2021-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 25, 2020 Filed Nov 30, 2020 23:48 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 12,990 | $50.05 | $650,149.50 |
DisclosureSEC source: 0000874015-20-000158 · edgar.xml · nonDerivative · entry 2 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,021 F2 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 13, 2019. F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.85 to $50.25, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) of this Form 4. Read SEC document |
| November 25, 2020 Filed Nov 30, 2020 23:48 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 12,990 | $39.87 | $517,911.30 |
DisclosureSEC source: 0000874015-20-000158 · edgar.xml · nonDerivative · entry 1 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,011 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/1/21. The purchase reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 13, 2019. Read SEC document |
| November 24, 2020 Filed Nov 26, 2020 00:04 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,590 | $0.00 Strike: $39.87 | $0.00 |
DisclosureSEC source: 0000874015-20-000152 · edgar.xml · derivative · entry 10 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,990 Underlying: Common Stock · 0 shares Expires 2021-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 24, 2020 Filed Nov 26, 2020 00:04 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 2,590 | $50.83 | $131,649.70 |
DisclosureSEC source: 0000874015-20-000152 · edgar.xml · nonDerivative · entry 6 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,021 F4 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 13, 2019. F6 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.50 to $51.00, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (6) of this Form 4. Read SEC document |
| November 24, 2020 Filed Nov 26, 2020 00:04 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 2,590 | $39.87 | $103,263.30 |
DisclosureSEC source: 0000874015-20-000152 · edgar.xml · nonDerivative · entry 5 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,611 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/1/21. The purchase reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 13, 2019. Read SEC document |
| November 23, 2020 Filed Nov 26, 2020 00:04 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 11,600 | $0.00 Strike: $39.87 | $0.00 |
DisclosureSEC source: 0000874015-20-000152 · edgar.xml · derivative · entry 9 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,580 Underlying: Common Stock · 0 shares Expires 2021-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 23, 2020 Filed Nov 26, 2020 00:04 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 500 | $0.00 Strike: $39.87 | $0.00 |
DisclosureSEC source: 0000874015-20-000152 · edgar.xml · derivative · entry 8 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Indirect · by wife Disclosed balance after: 0 Underlying: Common Stock · 0 shares Expires 2021-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 23, 2020 Filed Nov 26, 2020 00:04 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 11,600 | $50.11 | $581,276.00 |
DisclosureSEC source: 0000874015-20-000152 · edgar.xml · nonDerivative · entry 4 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,021 F4 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 13, 2019. F5 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.25, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (5) of this Form 4. Read SEC document |
| November 23, 2020 Filed Nov 26, 2020 00:04 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 11,600 | $39.87 | $462,492.00 |
DisclosureSEC source: 0000874015-20-000152 · edgar.xml · nonDerivative · entry 3 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,621 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/1/21. The purchase reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 13, 2019. Read SEC document |
| November 23, 2020 Filed Nov 26, 2020 00:04 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 500 | $50.00 | $25,000.00 |
DisclosureSEC source: 0000874015-20-000152 · edgar.xml · nonDerivative · entry 2 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Indirect · by wife Disclosed balance after: 1,581 F2 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person's wife on March 13, 2019. Read SEC document |
| November 23, 2020 Filed Nov 26, 2020 00:04 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 500 | $39.87 | $19,935.00 |
DisclosureSEC source: 0000874015-20-000152 · edgar.xml · nonDerivative · entry 1 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Indirect · by wife Disclosed balance after: 2,081 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/1/21. The purchase reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person's wife on March 13, 2019. Read SEC document |
| November 19, 2020 Filed Jan 7, 2021 02:17 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GiftCommon Stock | 31,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-21-000015 · edgar.xml · nonDerivative · entry 1 CROOKE STANLEY T · CIK 0000897667 · Director · Executive Chairman of Board 10b5-1 filing: Not disclosed Ownership: Indirect · By trust Disclosed balance after: 569,391 F1 · kind: Represents a bona fide gift to a charitable organization. Read SEC document |
| September 22, 2020 Filed Sep 23, 2020 22:44 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 50,000 | $50.41 | $2,520,460.00 |
DisclosureSEC source: 0000874015-20-000131 · edgar.xml · nonDerivative · entry 2 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Indirect · By trust Disclosed balance after: 650,391 F2 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on January 2, 2020 F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.02 to $50.70, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) of this Form 4 Read SEC document |
| September 21, 2020 Filed Sep 23, 2020 22:44 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 2,000 | $50.18 | $100,360.00 |
DisclosureSEC source: 0000874015-20-000131 · edgar.xml · nonDerivative · entry 1 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 1,581 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person's wife on January 2, 2020. Read SEC document |
| June 25, 2020 Filed Jun 26, 2020 23:47 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 9,914 | $60.11 | $595,906.75 |
DisclosureSEC source: 0000874015-20-000076 · edgar.xml · nonDerivative · entry 2 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,021 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on January 2, 2020. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.10 to $60.15, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) of this Form 4 Read SEC document |
| June 24, 2020 Filed Jun 26, 2020 23:47 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 5,000 | $58.80 | $294,000.00 |
DisclosureSEC source: 0000874015-20-000076 · edgar.xml · nonDerivative · entry 1 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,935 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on January 2, 2020. Read SEC document |
| June 19, 2020 Filed Jun 19, 2020 23:03 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 10,000 | $58.33 | $583,250.00 |
DisclosureSEC source: 0000874015-20-000072 · edgar.xml · nonDerivative · entry 3 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,935 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on January 2, 2020. F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.25 to $58.40, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) of this Form 4 Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 23:03 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 2,000 | $58.25 | $116,500.00 |
DisclosureSEC source: 0000874015-20-000072 · edgar.xml · nonDerivative · entry 2 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Indirect · By Wife Disclosed balance after: 3,581 F3 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person's wife on January 2, 2020. Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 23:03 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 15,000 | $57.90 | $868,521.00 |
DisclosureSEC source: 0000874015-20-000072 · edgar.xml · nonDerivative · entry 1 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,935 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on January 2, 2020. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.59 to $58.36, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) of this Form 4 Read SEC document |
| March 25, 2020 Filed Mar 27, 2020 23:05 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 1,000 | $47.00 | $47,000.00 |
DisclosureSEC source: 0000874015-20-000066 · edgar.xml · nonDerivative · entry 2 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Indirect · By Wife Disclosed balance after: 5,581 F2 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person's wife on January 2, 2020. Read SEC document |
| March 25, 2020 Filed Mar 27, 2020 23:05 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 15,000 | $47.00 | $705,000.00 |
DisclosureSEC source: 0000874015-20-000066 · edgar.xml · nonDerivative · entry 1 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,935 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on January 2, 2020. Read SEC document |
| March 19, 2020 Filed Mar 23, 2020 22:17 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 1,000 | $45.00 | $45,000.00 |
DisclosureSEC source: 0000874015-20-000062 · edgar.xml · nonDerivative · entry 3 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 6,581 F3 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person's wife on January 2, 2020. Read SEC document |
| March 19, 2020 Filed Mar 23, 2020 22:17 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 5,000 | $46.00 | $230,000.00 |
DisclosureSEC source: 0000874015-20-000062 · edgar.xml · nonDerivative · entry 2 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,545 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on January 2, 2020. Read SEC document |
| March 19, 2020 Filed Mar 23, 2020 22:17 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 10,000 | $44.75 | $447,546.00 |
DisclosureSEC source: 0000874015-20-000062 · edgar.xml · nonDerivative · entry 1 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,545 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on January 2, 2020. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.50 to $45.07, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) of this Form 4. Read SEC document |
| March 17, 2020 Filed Mar 19, 2020 17:55 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCOMMON STOCK | 4,349 | $45.00 | $195,705.00 |
DisclosureSEC source: 0000874015-20-000060 · edgar.xml · nonDerivative · entry 4 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,545 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on January 2, 2020. Read SEC document |
| March 17, 2020 Filed Mar 19, 2020 17:55 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCOMMON STOCK | 5,651 | $45.00 | $254,295.00 |
DisclosureSEC source: 0000874015-20-000060 · edgar.xml · nonDerivative · entry 3 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,894 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on January 2, 2020. Read SEC document |
| March 17, 2020 Filed Mar 19, 2020 17:55 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCOMMON STOCK | 5,421 | $44.50 | $241,234.50 |
DisclosureSEC source: 0000874015-20-000060 · edgar.xml · nonDerivative · entry 2 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,545 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on January 2, 2020. Read SEC document |
| March 17, 2020 Filed Mar 19, 2020 17:55 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCOMMON STOCK | 4,969 | $44.50 | $221,120.50 |
DisclosureSEC source: 0000874015-20-000060 · edgar.xml · nonDerivative · entry 1 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,966 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on January 2, 2020. Read SEC document |
| March 17, 2020 Filed Mar 27, 2020 23:01 UTC Amendment | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 4,349 | $45.00 | $195,705.00 |
DisclosureSEC source: 0000874015-20-000064 · edgar.xml · nonDerivative · entry 4 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,935 F1 · balance_after: The original Form 4 filed on March 19, 2020 reported 4,969 restricted stock units sold by the reporting person which has been revised by this amendment to reflect the actual amount of shares sold and beneficially owned by Mr. Crooke. Read SEC document |
| March 17, 2020 Filed Mar 27, 2020 23:01 UTC Amendment | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 5,651 | $45.00 | $254,295.00 |
DisclosureSEC source: 0000874015-20-000064 · edgar.xml · nonDerivative · entry 3 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,284 F1 · balance_after: The original Form 4 filed on March 19, 2020 reported 4,969 restricted stock units sold by the reporting person which has been revised by this amendment to reflect the actual amount of shares sold and beneficially owned by Mr. Crooke. Read SEC document |
| March 17, 2020 Filed Mar 27, 2020 23:01 UTC Amendment | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 5,421 | $44.50 | $241,234.50 |
DisclosureSEC source: 0000874015-20-000064 · edgar.xml · nonDerivative · entry 2 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,935 F1 · balance_after: The original Form 4 filed on March 19, 2020 reported 4,969 restricted stock units sold by the reporting person which has been revised by this amendment to reflect the actual amount of shares sold and beneficially owned by Mr. Crooke. Read SEC document |
| March 17, 2020 Filed Mar 27, 2020 23:01 UTC Amendment | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 4,579 | $44.50 | $203,765.50 |
DisclosureSEC source: 0000874015-20-000064 · edgar.xml · nonDerivative · entry 1 CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,356 F1 · shares: The original Form 4 filed on March 19, 2020 reported 4,969 restricted stock units sold by the reporting person which has been revised by this amendment to reflect the actual amount of shares sold and beneficially owned by Mr. Crooke. F1 · balance_after: The original Form 4 filed on March 19, 2020 reported 4,969 restricted stock units sold by the reporting person which has been revised by this amendment to reflect the actual amount of shares sold and beneficially owned by Mr. Crooke. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 23:28 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Units · Derivative | 3,317 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-20-000029 · edgar.xml · derivative · entry 9 CROOKE STANLEY T · CIK 0000897667 · Director · Executive Chairman of Board 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 6,627 Underlying: Common Stock · 3,317 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.